Violini V, Romanello A, Vannetti A, Alasino M, Copparoni C, Samper A, Papailiou MP

Language: Spanish
References: 13
Page: 147-150
PDF size: 253.00 Kb.

ABSTRACT

Streptococcal toxic shock syndrome is caused by group A streptococcus (pyogenes). The main role in pathogenesis is fulfilled by superantigens, which together with other factors of virulence of the GAS, antecedent of soft tissue injury and release of cytokines among others, are able to develop this serious infection, where there is a high mortality. We present the case of a male patient of 47 years of age, with no pathological history, who consults with the ward of our hospital due to general malaise with vomiting and diarrhea of 72 hours, with appearance of blackish brown plaques with serosal blisters in their surface and denuded areas, dying in less than 16 hours in an Intensive Care Unit.

REFERENCES

1. Martin PR, Hĝiby EA. Streptococcal serogroup A epidemic in Norway 1987-1988. Scandinavian Journal of Infectious Diseases. 1990; 22 (4): 421-429.

2. Stevens DL, Bryant AE. Severe group A streptococcal infections. In: Ferretti JJ, Stevens DL, Fischetti VA. Streptococcus pyogenes: basic biology to clinical manifestations. Oklahoma City: 2016. pp. 741-769.

3. DiPersio JR, File TM, Stevens DL, Gardner WG, Petropoulos G, Dinsa K. Spread of serious disease-producing M3 clones of group A Streptococcus among family members and health care workers. Clinical Infectious Diseases. 1996; 22 (3): 490-495.

4. Herold AH. Group A beta-hemolytic streptococcal toxic shock from a mild pharyngitis. The Journal of Family Practice. 1990; 31 (5): 549-551.

5. Barnham M. Nonsteroidal antiinflammatory drugs: concurrent or causative drugs in serious infection? Clinical Infectious Diseases. 1997; 25 (5): 1272-1273.

6. Lancefield RC. A serological differentiation of human and other groups of hemolytic streptococci. The Journal of Experimental Medicine. 1933; 57 (4): 571-595.

7. Bryant AE, Bayer CR, Huntington JD, Stevens DL. Group A streptococcal myonecrosis: increased vimentin expression after skeletal-muscle injury mediates the binding of Streptococcus pyogenes. The Journal of Infectious Diseases. 2006; 193 (12): 1685-1692.

8. Norrby-Teglund A, Basma H, Andersson J, McGeer A, Low DE, Kotb M. Varying titers of neutralizing antibodies to streptococcal superantigens in different preparations of normal polyspecific immunoglobulin G: implications for therapeutic efficacy. Clinical Infectious Diseases. 1998; 26 (3): 631-638.

9. Stevens DL, Bryant AE, Hackett SP, Chang A, Peer G, Kosanke S et al. Group A streptococcal bacteremia: the role of tumor necrosis factor in shock and organ failure. The Journal of Infectious Diseases. 1996; 173 (3): 619-626.

10. Stevens DL, Tanner MH, Winship J, Swarts R, Reis KM, Schlievert PM et al. Reappearance of scarlet fever toxin A among streptococci in the Rocky Mountain West: severe group A streptococcal infections associated with a toxic shock-like syndrome. The New England Journal of Medicine. 1989; 321 (1): 1-7.

11. Stevens DL, Bisno AL, Chambers HF, Dellinger EP, Goldstein EJ, Gorbach SL et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. Clinical Infectious Diseases. 2014; 59 (2): e10-e52.

12. Proft T, Fraser JD. Streptococcal superantigens: biological properties and potential role in disease. In: Ferretti JJ, Stevens DL, Fischetti VA. Streptococcus pyogenes: basic biology to clinical manifestations. Oklahoma City: 2016. pp. 1-32.

13. Young K, Khan Luni F, Yoon Y. Toxic shock syndrome an unusual organism. Am J Med Sci. 2016; 352 (1): 86-90.